Page 2 - உலகளாவிய ஒழுங்குமுறை வாழ்க்கைத்தொழில்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
EFSA expands opportunities for vitamin D fortification
nutraingredients.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nutraingredients.com Daily Mail and Mail on Sunday newspapers.
EFSA update expands opportunities for vitamin D fortification
nutraingredients.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nutraingredients.com Daily Mail and Mail on Sunday newspapers.
Yield10 Bioscience Announces Two New Hires as Camelina Business Plan Advances
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Yield10 Bioscience Announces Two New Hires as Camelina
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Share:
Basel, June 28, 2021 Novartis announced today the appointment of Rob Kowalski, Pharm.D., Global Head Regulatory Affairs and US Head of Drug Development as Chief People & Organization Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN), effective September 1, 2021.
Steven Baert, currently Chief People & Organization Officer, will step down from the Executive Committee of Novartis, effective June 30, 2021 after 15 years with the company and almost 8 years in position. Vicki Rawlinson, US Head People & Organization will lead the function ad-interim until Dr. Kowalski takes over.
Dr. Kowalski is a senior drug development and regulatory executive with over 25 years of industry experience. He has successfully built and led Global Regulatory Affairs, a large organization within the Novartis Drug Development with many interfaces into our commercial and R&D organizations on global and local levels. Prior